TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07097142: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Sponsor: NRG Oncology · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 486 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07097142 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07097142 Rescue Dossier →